327 related articles for article (PubMed ID: 31079535)
1. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Johnson RJ; Choi HK; Yeo AE; Lipsky PE
Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
[TBL] [Abstract][Full Text] [Related]
2. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
4. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
5. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
[TBL] [Abstract][Full Text] [Related]
6. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
7. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
8. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
[TBL] [Abstract][Full Text] [Related]
9. Pegloticase for chronic gout.
Anderson A; Singh JA
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
[TBL] [Abstract][Full Text] [Related]
10. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
11. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
[TBL] [Abstract][Full Text] [Related]
12. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Schlesinger N; Lipsky PE
Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
[TBL] [Abstract][Full Text] [Related]
13. Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Keenan RT; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2022 May; 40(5):1006-1010. PubMed ID: 35238750
[TBL] [Abstract][Full Text] [Related]
14. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.
Pillinger MH; Fields TR; Yeo AE; Lipsky PE
J Rheumatol; 2020 Apr; 47(4):605-612. PubMed ID: 31203212
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
16. Development of a multivariable improvement measure for gout.
Schlesinger N; Edwards NL; Yeo AE; Lipsky PE
Arthritis Res Ther; 2020 Jun; 22(1):164. PubMed ID: 32600452
[TBL] [Abstract][Full Text] [Related]
17. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
[TBL] [Abstract][Full Text] [Related]
19. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.
Yood RA; Ottery FD; Irish W; Wolfson M
BMC Res Notes; 2014 Jan; 7():54. PubMed ID: 24447425
[TBL] [Abstract][Full Text] [Related]
20. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
Yeter KC; Ortiz EC; Arkfeld DG
Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
